Earnings Call · Q4 FY2021·2022-03-28

Q4 21EPS +93.33%·Rev n/aQ3 21EPS -63.64%·Rev n/aQ2 21EPS -100.00%*·Rev n/aQ1 21EPS +86.67%·Rev n/a⚠ consensus missing

Definium Therapeutics, Inc. DFTX

Rob Barrow — Chief Executive Officer

Dan Karlin — Chief Scientific Officer

Miri Halperin Wernli — Head of Research and Development

+1.7%1d on move date+0.5% vs SPY3d−4.3%5d−3.4%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DFTX calls or request research access.

More DFTX calls Browse calls Request research access